IDEAYA Biosciences announced it will present updated clinical trial data for its cancer drug darovasertib in uveal melanoma and IDE849 in small cell lung carcinoma at the 2026 European Society of Medical Oncology (ESMO) meeting. The data includes results from multiple ongoing Phase 2/3 trials, highlighting the potential of darovasertib as a new treatment option for uveal melanoma patients. IDEAYA's partner Hengrui Pharma will also share Phase 1 study results of IDE849 in China. These presentations underscore IDEAYA's progress in developing targeted cancer therapies and set the stage for upcoming registrational trials and potential new treatment approvals.
Fangzhou Inc. has launched Kyinsu®, the world's first once-weekly basal insulin/GLP-1 receptor agonist combination therapy, on its AI-powered Internet hospital platform in China, the first global market for this treatment. This therapy reduces insuli...
Neutron Holdings received a buy rating due to its strong 29% year-over-year revenue growth to $887 million in 2025 and a 32% revenue increase in Q1 2026. The company also reported healthy unit economics with a 24.6% adjusted EBITDA margin and $103.8 ...
Bitcoin options data reveals a bullish medium-term outlook with call options dominating open interest, signaling trader confidence in price gains. However, recent trading shows increased put option volume, indicating that traders are hedging against ...
Eva Live Inc. announced a plan to acquire a 51% stake in Airbeam Wireless Technologies for about $16 million, with an option to buy the rest. This move gives Eva Live access to over 260 patents and advanced millimeter-wave technology, accelerating it...
Bitcoin has recovered from a July 1 low of $57,800 to trade around $64,000, supported by long-term holders who are holding rather than selling. The current price zone is defended by traders to avoid losses, but the market floor is still forming. Key ...
